Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of interest.
Hazard Rate01:11

Hazard Rate

The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Atrial premature beats preceding episodes of paroxysmal atrial fibrillation: factorial analysis of a prediction system.

Pacing and clinical electrophysiology : PACE·1997
Same author

Exercise-induced T-wave alternans as a marker of high risk in patients with hypertrophic cardiomyopathy.

Japanese circulation journal·1997
Same author

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.

Circulation·1997
Same author

Chlamydia pneumoniae and coronary heart disease.

BMJ (Clinical research ed.)·1997
Same author

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.

Lancet (London, England)·1997
Same author

Use of troponin-T concentration and kinase isoforms for quantitation of myocardial injury induced by radiofrequency catheter ablation.

European heart journal·1997

相关实验视频

Updated: Jul 19, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

洛萨坦与卡普托普利尔对症状心力衰竭患者的死亡率的影响:随机试验 - - 洛萨坦心力衰竭生存研究ELITE II.

B Pitt1, P A Poole-Wilson, R Segal

  • 1Division of Cardiology, University of Michigan School of Medicine, Ann Arbor 48109-0366, USA. b.pitt@umich.edu

Lancet (London, England)
|May 23, 2000
PubMed
概括

在老年心力衰竭患者中,洛萨尔坦与卡普托普里尔相比没有改善存活率. 然而,洛萨坦的耐受性更好,由于咳等不良反应而停止治疗的患者较少.

相关实验视频

Last Updated: Jul 19, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 临床试验 临床试验

背景情况:

  • 在老年心力衰竭患者中,ELITE研究表明,洛沙坦 ( ангиотензин II 抗剂) 对卡波普利 ( ангиотензин转化酶抑制剂) 的生存益处更大.
  • 这促使进一步调查,以确认洛萨坦在生存和耐受性方面的优越性.

研究的目的:

  • 确认洛萨坦在改善心力衰竭老年患者的存活率方面是否优于卡普托普利.
  • 为了评估洛萨坦在这个患者群体中是否比卡普托普里尔更能耐受.

主要方法:

  • 一个双盲,随机,受控试验 (ELITE II) 涉及3,152名老年患者 (≥60岁) 患有心力衰竭 (NYHA类II-IV) 和减少喷射率 (≤40%).
  • 患者被随机分配给接受洛萨坦或卡普托普里尔,治疗量为最佳剂量.
  • 主要终点包括全因死亡率和突然死亡/复苏性逮捕;安全性和耐受性被评估.

主要成果:

  • 洛萨坦和卡波普利尔组之间所有原因的死亡率没有显著差异 (11.7%对10.4%年均).
  • 两组之间突然死亡或复苏逮捕率没有显著差异 (9.0%对7.3%).
  • 与卡波普利尔相比,由于副作用而停止服用洛萨坦的患者数量显著减少 (9.7%vs14.7%),特别是咳减少 (0.3%vs2.7%).

结论:

  • 洛沙坦在改善老年心力衰竭患者的存活率方面没有表现出优于卡普托普利的优势.
  • 洛萨坦比卡普托普利尔耐受得更好,由于不良事件,特别是咳,治疗中止的发生率较低.